These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 31097698)

  • 1. A high-throughput screen indicates gemcitabine and JAK inhibitors may be useful for treating pediatric AML.
    Drenberg CD; Shelat A; Dang J; Cotton A; Orwick SJ; Li M; Jeon JY; Fu Q; Buelow DR; Pioso M; Hu S; Inaba H; Ribeiro RC; Rubnitz JE; Gruber TA; Guy RK; Baker SD
    Nat Commun; 2019 May; 10(1):2189. PubMed ID: 31097698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. F14512, a polyamine-vectorized anti-cancer drug, currently in clinical trials exhibits a marked preclinical anti-leukemic activity.
    Kruczynski A; Pillon A; Créancier L; Vandenberghe I; Gomes B; Brel V; Fournier E; Annereau JP; Currie E; Guminski Y; Bonnet D; Bailly C; Guilbaud N
    Leukemia; 2013 Nov; 27(11):2139-48. PubMed ID: 23568148
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of artemisinins for the treatment of acute myeloid leukemia.
    Drenberg CD; Buaboonnam J; Orwick SJ; Hu S; Li L; Fan Y; Shelat AA; Guy RK; Rubnitz J; Baker SD
    Cancer Chemother Pharmacol; 2016 Jun; 77(6):1231-43. PubMed ID: 27125973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. JAK-STAT inhibitor as a potential therapeutic opportunity in AML patients resistant to cytarabine and epigenetic therapy.
    Babu G; Chaudhuri P; Rajappa M; Biswas M; Sansar B; Rajegowda C; Radhakrishnan A; Advani J; Tewary B; Radhakrishnan P; Thiyagarajan S; Chatterjee A; Upadhayaya RS; Majumder PK
    Cancer Biol Ther; 2021 Jan; 22(1):66-78. PubMed ID: 33356802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination screening in vitro identifies synergistically acting KP372-1 and cytarabine against acute myeloid leukemia.
    Österroos A; Kashif M; Haglund C; Blom K; Höglund M; Andersson C; Gustafsson MG; Eriksson A; Larsson R
    Biochem Pharmacol; 2016 Oct; 118():40-49. PubMed ID: 27565890
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The interaction of gemcitabine and cytarabine on murine leukemias L1210 or P388 and on human normal and leukemic cell growth in vitro.
    Lech-Maranda E; Korycka A; Robak T
    Haematologica; 2000 Jun; 85(6):588-94. PubMed ID: 10870114
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved treatment results in high-risk pediatric acute myeloid leukemia patients after intensification with high-dose cytarabine and mitoxantrone: results of Study Acute Myeloid Leukemia-Berlin-Frankfurt-Münster 93.
    Creutzig U; Ritter J; Zimmermann M; Reinhardt D; Hermann J; Berthold F; Henze G; Jürgens H; Kabisch H; Havers W; Reiter A; Kluba U; Niggli F; Gadner H
    J Clin Oncol; 2001 May; 19(10):2705-13. PubMed ID: 11352963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The outcomes of relapsed acute myeloid leukemia in children: Results from the Japanese Pediatric Leukemia/Lymphoma Study Group AML-05R study.
    Moritake H; Tanaka S; Miyamura T; Nakayama H; Shiba N; Shimada A; Terui K; Yuza Y; Koh K; Goto H; Kakuda H; Saito A; Hasegawa D; Iwamoto S; Taga T; Adachi S; Tomizawa D
    Pediatr Blood Cancer; 2021 Jan; 68(1):e28736. PubMed ID: 32991072
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The novel phospholipid mimetic KPC34 is highly active against preclinical models of Philadelphia chromosome positive acute lymphoblastic leukemia.
    Alexander PM; Caudell DL; Kucera GL; Pladna KM; Pardee TS
    PLoS One; 2017; 12(6):e0179798. PubMed ID: 28644853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MTH1 Inhibitor TH1579 Induces Oxidative DNA Damage and Mitotic Arrest in Acute Myeloid Leukemia.
    Sanjiv K; Calderón-Montaño JM; Pham TM; Erkers T; Tsuber V; Almlöf I; Höglund A; Heshmati Y; Seashore-Ludlow B; Nagesh Danda A; Gad H; Wiita E; Göktürk C; Rasti A; Friedrich S; Centio A; Estruch M; Våtsveen TK; Struyf N; Visnes T; Scobie M; Koolmeister T; Henriksson M; Wallner O; Sandvall T; Lehmann S; Theilgaard-Mönch K; Garnett MJ; Östling P; Walfridsson J; Helleday T; Warpman Berglund U
    Cancer Res; 2021 Nov; 81(22):5733-5744. PubMed ID: 34593524
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gemtuzumab Ozogamicin Improves Event-Free Survival and Reduces Relapse in Pediatric
    Pollard JA; Guest E; Alonzo TA; Gerbing RB; Loken MR; Brodersen LE; Kolb EA; Aplenc R; Meshinchi S; Raimondi SC; Hirsch B; Gamis AS
    J Clin Oncol; 2021 Oct; 39(28):3149-3160. PubMed ID: 34048275
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AML cells are differentially sensitive to chemotherapy treatment in a human xenograft model.
    Wunderlich M; Mizukawa B; Chou FS; Sexton C; Shrestha M; Saunthararajah Y; Mulloy JC
    Blood; 2013 Mar; 121(12):e90-7. PubMed ID: 23349390
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Response-guided chemotherapy for pediatric acute myeloid leukemia without hematopoietic stem cell transplantation in first complete remission: Results from protocol DB AML-01.
    De Moerloose B; Reedijk A; de Bock GH; Lammens T; de Haas V; Denys B; Dedeken L; van den Heuvel-Eibrink MM; Te Loo M; Uyttebroeck A; Van Damme A; Van der Werff-Ten Bosch J; Zsiros J; Kaspers G; de Bont E
    Pediatr Blood Cancer; 2019 May; 66(5):e27605. PubMed ID: 30623572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The safety and efficacy of clofarabine in combination with high-dose cytarabine and total body irradiation myeloablative conditioning and allogeneic stem cell transplantation in children, adolescents, and young adults (CAYA) with poor-risk acute leukemia.
    Hochberg J; Zahler S; Geyer MB; Chen N; Krajewski J; Harrison L; Militano O; Ozkaynak MF; Cheerva AC; Talano J; Moore TB; Gillio AP; Walters MC; Baxter-Lowe LA; Hamby C; Cairo MS
    Bone Marrow Transplant; 2019 Feb; 54(2):226-235. PubMed ID: 29899571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decreased relapsed rate and treatment-related mortality contribute to improved outcomes for pediatric acute myeloid leukemia in successive clinical trials.
    Alexander TB; Wang L; Inaba H; Triplett BM; Pounds S; Ribeiro RC; Pui CH; Rubnitz JE
    Cancer; 2017 Oct; 123(19):3791-3798. PubMed ID: 28556917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proteasome inhibition enhances the efficacy of volasertib-induced mitotic arrest in AML in vitro and prolongs survival in vivo.
    Schnerch D; Schüler J; Follo M; Felthaus J; Wider D; Klingner K; Greil C; Duyster J; Engelhardt M; Wäsch R
    Oncotarget; 2017 Mar; 8(13):21153-21166. PubMed ID: 28416751
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting SAMHD1 with the Vpx protein to improve cytarabine therapy for hematological malignancies.
    Herold N; Rudd SG; Ljungblad L; Sanjiv K; Myrberg IH; Paulin CB; Heshmati Y; Hagenkort A; Kutzner J; Page BD; Calderón-Montaño JM; Loseva O; Jemth AS; Bulli L; Axelsson H; Tesi B; Valerie NC; Höglund A; Bladh J; Wiita E; Sundin M; Uhlin M; Rassidakis G; Heyman M; Tamm KP; Warpman-Berglund U; Walfridsson J; Lehmann S; Grandér D; Lundbäck T; Kogner P; Henter JI; Helleday T; Schaller T
    Nat Med; 2017 Feb; 23(2):256-263. PubMed ID: 28067901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DNA Methylation-Based Epigenetic Repression of SLC22A4 Promotes Resistance to Cytarabine in Acute Myeloid Leukemia.
    Buelow DR; Anderson JT; Pounds SB; Shi L; Lamba JK; Hu S; Gibson AA; Goodwin EA; Sparreboom A; Baker SD
    Clin Transl Sci; 2021 Jan; 14(1):137-142. PubMed ID: 32905646
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytoprotective autophagy maintains leukemia-initiating cells in murine myeloid leukemia.
    Sumitomo Y; Koya J; Nakazaki K; Kataoka K; Tsuruta-Kishino T; Morita K; Sato T; Kurokawa M
    Blood; 2016 Sep; 128(12):1614-24. PubMed ID: 27480114
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimizing Therapeutic Effect of Aurora B Inhibition in Acute Myeloid Leukemia with AZD2811 Nanoparticles.
    Floc'h N; Ashton S; Taylor P; Trueman D; Harris E; Odedra R; Maratea K; Derbyshire N; Caddy J; Jacobs VN; Hattersley M; Wen S; Curtis NJ; Pilling JE; Pease EJ; Barry ST
    Mol Cancer Ther; 2017 Jun; 16(6):1031-1040. PubMed ID: 28292940
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.